Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Bruce A. Littlefield"'
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Mary Ann Jordan, Duncan A. Proctor, Barbara S. Slusher, Stuart C. Feinstein, Bruce A. Littlefield, Ying Wu, Leslie Wilson, Krystyna M. Wozniak, R. B. Bromberg, Brett M. Cook
Publikováno v:
Neurotoxicity Research. 34:677-692
The reversibility of chemotherapy-induced peripheral neuropathy (CIPN), a disabling and potentially permanent side effect of microtubule-targeting agents (MTAs), is becoming an increasingly important issue as treatment outcomes improve. The molecular
Autor:
Chiara Bellio, Esther Zamora, Marta Emperador, Bruce A. Littlefield, Cristina Saura, Josep Villanueva, Laia Garrigós
Publikováno v:
Cancer Research. 81:993-993
Microtubule-targeting agents (MTAs) constitute a diverse group of chemical compounds that bind to microtubules and affect their structure and function. Disruption of microtubules induces various cellular responses, often leading to cell cycle arrest
Eribulin mesylate (eribulin) is a synthetic analogue of the marine-sponge natural product halichondrin B. Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell types in vitro and in vivo, and is used for the tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a030d57633f34a0f89fcfe21e08c8a1b
https://lirias.kuleuven.be/handle/123456789/636778
https://lirias.kuleuven.be/handle/123456789/636778
Autor:
James J. Vornov, Ying Wu, Kenichi Nomoto, Larisa Reyderman, Nancy Wong, Christopher DesJardins, Yanke Yu, Bruce A. Littlefield, Krystyna M. Wozniak, W. George Lai, Barbara S. Slusher
Publikováno v:
Cancer Research. 76:3332-3339
Chemotherapy-induced peripheral neuropathy is a dose-limiting side effect of many antineoplastic agents, but the mechanisms underlying the toxicities are unclear. At their MTDs, the microtubule-binding drugs paclitaxel and ixabepilone induce more sev
Autor:
Bram Boecks, Bruce A. Littlefield, Amy Weaver, Elodie Modave, Patrick Schöffski, Agnieszka Wozniak, Diether Lambrechts
Publikováno v:
Cancer Research. 80:4280-4280
Background. The recent randomized phase 3 trial Eisai Study 309 evaluated efficacy of eribulin (ERI) compared to dacarbazine (DTIC) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS). Improved overall survival (OS) in ERI-treated patients led to
Publikováno v:
Cancer Research. 80:1924-1924
Background: Eribulin mesylate, a synthetic analog of the marine sponge natural product halichondrin B, is a microtubule dynamics inhibitor that acts via both cytotoxic antimitotic mechanisms as well as non-cytotoxic effects on tumor vasculature, tumo
Publikováno v:
Cancer Research. 80:5522-5522
Eribulin, a synthetic analog of the marine sponge natural product halichondrin B, is approved in the US for certain patients with advanced breast cancer or liposarcoma. Its mechanisms of action include both cytotoxic, antimitotic effects as well as n
Autor:
Olga Méndez, Bruce A. Littlefield, Chiara Bellio, Cándida Salvans, Cristina Saura, Esther Zamora, Nathalie Meo-Evoli, Juan M. Duran, Josep Villanueva, Laia Garrigós
Publikováno v:
Molecular Cancer Therapeutics. 18:A036-A036
Microtubules are major components of the cytoskeleton. They are involved in a wide variety of cell functions including attribution to cell shape, motility, intracellular trafficking and mitotic spindle formation. Therefore, microtubules have gained s
Autor:
Bruce A. Littlefield, Angel Patel, Thaddeus D. Allen, Gerald Post, Lindsay Lambert, Benjamin Lewis, Christina Lopes
Publikováno v:
Molecular Cancer Therapeutics. 18:C098-C098
Eribulin is a microtubule dynamics inhibitor that is currently in clinical use for treatment of certain patients with advanced breast cancer or liposarcoma. FDA approval for both indications was based on extension of overall survival. Based on eribul